Study reveals molecular causes of brain asymmetry

Scientists may have solved one of the most puzzling and persistent mysteries in neuroscience: why some people are "right-brained" while others are "left-brained."

The answer lies in how certain genes on each side of the brain are switched "on" and "off" through a process called epigenetic regulation. The findings may explain why Parkinson's disease and other neurological disorders frequently affect one side of the body first, a revelation that has far-reaching implications for development of potential future treatments.

The study was led by Van Andel Institute's Viviane Labrie, Ph.D., and published in the journal Genome Biology.

The mechanisms underlying brain asymmetry have been an elephant in the room for decades. It's thrilling to finally uncover its cause, particularly given its potential for helping us better understand and, hopefully one day, better treat diseases like Parkinson's."

Viviane Labrie, Ph.D., Van Andel Institute

Each cell in the brain has the same genes but it is epigenetics that dictate whether those genes are switched "on" or "off." Labrie and her collaborators found numerous epigenetic differences between the hemispheres of healthy brains that are linked to variations in gene activity. Notably, these differences, or asymmetry, could make one side of the brain more vulnerable to neurological diseases.

For example, epigenetic abnormalities on one side of the brain could make that hemisphere more susceptible to the processes that cause the death of brain cells in Parkinson's. The differences in cell death across hemispheres leads to the appearance of the disease's hallmark symptoms, such as tremor, on one side of the body before the other. As the disease progresses, symptoms on the side first affected often are more severe than symptoms on the other side of the body.

The findings also give scientists a vital window into the various biological pathways that contribute to symptom asymmetry in Parkinson's, including brain cell development, immune function and cellular communication.

"We all start out with prominent differences between the left and right sides of our brains. As we age, however, our hemispheres become more epigenetically similar. For Parkinson's, this is significant: people whose hemispheres are more alike early in life experienced faster disease progression, while people whose hemispheres were more asymmetric had slower disease progression," Labrie said. "Many of these changes are clustered around genes known to impact Parkinson's risk. There is huge potential to translate these findings into new therapeutic strategies."

Labrie is already starting to look at this phenomenon in other neurological diseases like Alzheimer's.

The study is one of the first to parse the molecular causes of brain asymmetry. Early research on the left versus right brain was conducted in the mid-20th century by Roger Sperry, whose groundbreaking work with split-brain patients earned him a Nobel Prize.

Source:
Journal reference:

Li, P., et al. (2020) Hemispheric asymmetry in the human brain and in Parkinson’s disease is linked to divergent epigenetic patterns in neurons. Genome Biology. doi.org/10.1186/s13059-020-01960-1.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics